EUVIMEDEUVIMED entdecken
Open Access

Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform

Antoni Serrano-Martí, Ana Armiñán, Inmaculada Conejos-Sánchez, Daniela Mittermüller, Shang-Wei Li, Paula Tenhaeff Lackschewitz, Esther Roselló-Sastre, Matthias Gunzer, Horacio Cabral, María J Vicent

Theranostics · 2026

DOI: 10.7150/thno.123005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Antoni Serrano-Martí und 9 weiteren Autor:innen. Beteiligte Einrichtung: Polymer Therapeutics Laboratory, Príncipe Felipe Research Center (CIPF), Valencia, Spain. Hauptthemen laut MEDLINE: Bone Neoplasms, Docetaxel, Prostatic Neoplasms, Castration-Resistant, Nanomedicine. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Bone metastases - common in metastatic castration-resistant prostate cancer (mCRPC) - lead to severe complications and currently suffer from limited therapeutic options. Poor solubility, systemic toxicity, and therapeutic resistance hamper conventional approaches, such as docetaxel (Dtx) treatment. Nanomedicine-based strategies - including polymer-drug conjugates - can help overcome said limitations through enhanced tumor targeting and reduced unwanted side effects in healthy tissues.

Methods

An intratibial bone mCRPC mouse model - used to recapitulate tumor growth and microenvironmental dynamics - was developed and characterized. A poly-L-glutamic acid (PGA)-Dtx) conjugate synthesized to enhance Dtx delivery and efficacy was also characterized in terms of size, zeta potential, drug loading, and pH-dependent release. In vivo evaluations included tumor growth monitoring by bioluminescence imaging, cathepsin K activity from tumor by fluorescence imaging, bone damage evaluation by micro-computed tomography, tumor vasculature by light-sheet fluorescent microscopy, cell population at tumor site by histology, modulation of blood cell populations by tumor and treatment by hematology, and biodistribution of PGA-Dtx using fluorescent imaging and intravital microscopy.

Results

Our intratibial bone mCRPC model supported reliable tumor establishment, progressive osteolytic damage and vascularization, and systemic inflammation. PGA-Dtx displayed optimal properties (6.6 nm size, -24.1 mV zeta potential, 3.3 mol % drug loading) and supported lower but sustained Dtx release at acidic pH. The enhanced tumor accumulation following PGA-Dtx administration significantly suppressed tumor growth in vivo, normalized cathepsin K activity levels, and reduced bone damage while avoiding the systemic toxicity associated with free Dtx.

Conclusions

Our intratibial bone mCRPC mouse model provides a robust platform for studying PCa bone metastases and evaluating nanomedicine efficacy. PGA-Dtx displays promise as a safe and effective therapy for mCRPC, offering improved drug delivery and reduced systemic side effects, which supports the translational potential of polymer-drug conjugates in mCRPC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsDocetaxelProstatic Neoplasms, Castration-ResistantNanomedicineAntineoplastic AgentsMaleAnimalsMiceDisease Models, AnimalHumansPolyglutamic AcidCell Line, Tumor

Stichwörter der Autor:innen

bone metastasisdocetaxelnanomedicinepolymer-drug conjugatesprostate cancer

Substanzen

DocetaxelAntineoplastic AgentsPolyglutamic Acid

Autor:innen und Institutionen

  • Polymer Therapeutics Laboratory, Príncipe Felipe Research Center (CIPF), Valencia, Spain.
  • Centro de Investigación médica en Red Cáncer (CIBERONC), Madrid, Spain.
  • Institute for Experimental Immunology and Imaging, University Hospital, University of Duisburg-Essen, Essen, Germany.
  • Institute for Virology, University Hospital, University of Duisburg-Essen, Essen, Germany.
  • Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Dortmund, Germany.
  • Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.

Zitieren

APA

Serrano-Martí, A., Armiñán, A., Conejos-Sánchez, I., Mittermüller, D., Li, S. W., Lackschewitz, P. T., Roselló-Sastre, E., Gunzer, M., Cabral, H., & Vicent, M. J. (2026). Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform. Theranostics. https://doi.org/10.7150/thno.123005

Vancouver

Serrano-Martí A, Armiñán A, Conejos-Sánchez I, Mittermüller D, Li SW, Lackschewitz PT, et al. Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform. Theranostics. 2026. doi:10.7150/thno.123005

BibTeX
@article{SerranoMart2026,
  author = {Serrano-Martí, Antoni and Armiñán, Ana and Conejos-Sánchez, Inmaculada and Mittermüller, Daniela and Li, Shang-Wei and Lackschewitz, Paula Tenhaeff and Roselló-Sastre, Esther and Gunzer, Matthias and Cabral, Horacio and Vicent, María J},
  title = {Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.123005}
}
Kostenlos starten →